16 Jan 2023 22:54 CET

Issuer

Thor Medical ASA

Oslo, Norway, 16 January 2023

Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") notes the
publication of a letter on 10 January 2023 by North Energy ASA, the largest
shareholder of the Company holding approximately 16.5% of the outstanding votes
and shares in the Company.

In the letter, North Energy requests additional financial information to be
published to all shareholders in the upcoming Q4 report due on 28 February 2023;
and secondly that the Company pre-announce certain key preliminary financial
information prior to the Q4 report (no later than 16 January 2023).

Nordic Nanovector confirms that it will report its results in line with the Oslo
Børs regulations on the specified date.

For further information, please contact:

IR enquiries

Malene Brondberg, Interim CEO and CFO of Nordic Nanovector

+ 44 7561 431 762

ir@nordicnanovector.com

International Media: Frazer Hall / Mark Swallow (MEDiSTRAVA Consulting)

+44 203 928 6900

nordicnanovector@medistrava.com


Source

Nordic Nanovector ASA

Provider

Oslo Børs Newspoint

Company Name

NORDIC NANOVECTOR

ISIN

NO0010597883

Symbol

NANOV

Market

Oslo Børs